← All trials
NCT01658020
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2012
- Primary completion
- Jan 1, 2014
- Completion date
- Aug 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 345
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- DongWha Pharmaceutical CompanyLead sponsor
- Cha Medical UniversityCollaborator
- Chungnam National UniversityCollaborator
- Chungbuk National UniversityCollaborator
- Hanyang UniversityCollaborator
- Inje UniversityCollaborator
- Ajou UniversityCollaborator
- Chonnam National UniversityCollaborator
- Konkuk UniversityCollaborator
- Yonsei UniversityCollaborator
- Chonbuk National UniversityCollaborator
- Korea UniversityCollaborator
- Konyang UniversityCollaborator
- Kyung Hee UniversityCollaborator
- Sungkyunkwan UniversityCollaborator
- Yeungnam UniversityCollaborator
- Gachon UniversityCollaborator
- University of UlsanOverall official - principal investigator
- University of UlsanCollaborator
- KangWon National UniversityCollaborator
- Catholic University of KoreaCollaborator
- Chosun UniversityCollaborator
- Dongguk UniversityCollaborator
- Gyeongsang UniversityCollaborator
- Hallym UniversityCollaborator
- Keimyung UniversityCollaborator
- Wonju Christian HospitalCollaborator
- Ewha Womans UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.